法国类风湿关节炎生物疗法的经济影响。

Economic impact of rheumatoid arthritis (RA) biotherapies in France.

机构信息

Département d'information médicale, hôpital Léopold-Bellan, 19-21, rue Vercingétorix, 75674 Paris cedex 14, France.

出版信息

Joint Bone Spine. 2010 Jul;77(4):319-24. doi: 10.1016/j.jbspin.2010.04.001. Epub 2010 May 20.

DOI:10.1016/j.jbspin.2010.04.001

PMID:20493751

Abstract

OBJECTIVE

Determining the economic impact of rheumatoid arthritis (RA) biotherapies in France.

METHOD

The number of patients on RA biotherapy in France was estimated from the French national medical information system program (PMSI) database using the 2007 hospital data. The cost of each biotherapy was calculated on a theoretical basis (French national health authority (HAS) recommendations) and on real-life setting, using 'real-life' setting data. In order to calculate the economic impact of the biotherapies, the cost of management with each biotherapy was applied to the RA patient population taking into account the market share of each biotherapy.

RESULTS

The number of patients with RA estimated was 15,873. Management costs ranged from 11,576 to 21,128 euro for the theoretical management scenario and from 6,451 to 19,618 euro for the real-life scenario. The overall cost was 222 million euro (real-life setting). TNF antagonists (adalimumab, etanercept, infliximab) were prescribed for 82% of the patient population and accounted for 80% of the annual overall cost of theoretical management and 84% of the cost of the real-life setting, respectively. Other biotherapies (abatacept, rituximab) were prescribed for 18% of the patients and accounted for 20 and 16% of the annual overall cost of the theoretical setting and real-life setting. Outpatient biotherapy was prescribed for 61% of the patient population and generated 68 and 71% of the total costs.

CONCLUSION

The data constitutes an initial inventory of the economic impact of RA biotherapies in France.

摘要

目的

确定法国类风湿关节炎（RA）生物疗法的经济影响。

方法

根据 2007 年医院数据，使用法国国家医疗信息系统计划（PMSI）数据库估算法国接受 RA 生物疗法的患者人数。根据法国国家卫生署（HAS）的建议和实际情况，基于理论基础和实际情况计算每种生物疗法的成本。为了计算生物疗法的经济影响，将每种生物疗法的管理成本应用于考虑每种生物疗法市场份额的 RA 患者人群。

结果

估计的 RA 患者人数为 15873 人。管理成本在理论管理方案中从 11576 欧元到 21128 欧元不等，在实际方案中从 6451 欧元到 19618 欧元不等。总体成本为 2.22 亿欧元（实际方案）。TNF 拮抗剂（阿达木单抗、依那西普、英夫利昔单抗）用于 82%的患者人群，占理论管理年度总成本的 80%和实际方案成本的 84%。其他生物疗法（阿巴西普、利妥昔单抗）用于 18%的患者，占理论设置和实际设置年度总成本的 20%和 16%。门诊生物疗法用于 61%的患者人群，产生 68%和 71%的总费用。